When can NIPT be done?
From gestational weeks when adequate fetal fraction can be obtained. Timing depends on gestational age, clinical context, and the selected panel — typically from week 10 for NIPTGEN PLUS.
Non-Invasive Prenatal Testing (NIPT) analyzes cell-free DNA circulating in maternal blood during pregnancy.

A portion of cfDNA in maternal circulation is placental in origin and carries pregnancy-related genetic information. Advanced genomic analysis can provide information about the chance of certain chromosomal anomalies.
From gestational weeks when adequate fetal fraction can be obtained. Timing depends on gestational age, clinical context, and the selected panel — typically from week 10 for NIPTGEN PLUS.
Screening is not diagnosis. Results are interpreted by the patient’s clinician with other pregnancy findings.
Fetal fraction refers to the proportion of placental cfDNA within the total cell-free DNA in maternal blood.
Adequate fetal fraction is one of the important quality parameters for reliable NIPT analysis.
In some cases, a new blood sample may be required due to low fetal fraction.
The clinician selects the appropriate prenatal screening option.
A maternal blood sample is collected under required conditions.
cfDNA is evaluated with advanced genomic methods.
Analysis data and quality parameters including fetal fraction are reviewed.
Results are prepared as a structured genetic screening report.
The clinician interprets results with clinical information and other findings.